|
|
|||
|
||||
OverviewHormones, Volume 142, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Estrogen receptor binding mechanism with agonist and antagonist, Biomarker Identification of Medullary Thyroid Carcinoma from Gene Expression Profiles Considering without-treatment and with-treatment Studies – A Bioinformatics approach, Exploring the Role of Estrogen and Progestins in Breast Cancer: A Genomic Approach to Diagnosis, Structural insights on ER-alpha, ER-Beta, progesterone and their drug-targets interactions in Breast cancer, The predictive ability of myokines in patients with chronic heart failure, and much more. Other chapters cover Endogenous and artificial regulators of pituitary glycoprotein hormone receptors, Insight into vitamin D3 action within the ovary - basic and clinical aspects, Hormonal basis of seasonal changes in metabolism, Viral mimicry and endocrine system: Divulging the importance in host-microbiome crosstalk, Recombinant hormones as biopharmaceuticals: past, present and future, Thyroid hormone biosynthesis and its role in brain development and maintenance, and much more. Full Product DetailsAuthor: Rossen Donev (Head of Research, MicroPharm Limited, UK)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Weight: 0.860kg ISBN: 9780443193460ISBN 10: 0443193460 Pages: 456 Publication Date: 23 July 2024 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsAuthor InformationRossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications. Tab Content 6Author Website:Countries AvailableAll regions |